Risk factors for malignant transformation of hepatocellular adenoma to hepatocellular carcinoma: protocol for systematic review and meta-analysis.
hepatobiliary disease
hepatobiliary surgery
hepatobiliary tumours
hepatology
risk management
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
10 08 2021
10 08 2021
Historique:
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
14
8
2021
Statut:
epublish
Résumé
Hepatocellular adenomas (HCAs) are solid liver tumours that are usually found incidentally during routine medical check-ups. Multiple modifiable and non-modifiable factors constitute a risk for the malignant transformation of HCAs to hepatocellular carcinoma (HCC), which has emerged to be one of the fastest growing causes of cancer-related mortality globally. This study protocol for a planned systematic review and meta-analysis documents the methodological approach to identify risk factors and their risk estimates for the transformation from HCA to HCC. Two independent reviewers will systematically search and extract data from studies in patients of all ages published between January 1970 and June 2021 on PubMed, MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature, Scopus Web of Science, Ovid, The Cochrane Hepatobiliary Group Controlled Trials Register and The Cochrane Central Register of Controlled Trials by using an No ethical approval is required as we will use and analyse data from previously published studies in which informed consent was obtained. The results will be disseminated in a peer-reviewed journal on completion. CRD42020206578.
Identifiants
pubmed: 34376442
pii: bmjopen-2020-045733
doi: 10.1136/bmjopen-2020-045733
pmc: PMC8354264
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e045733Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Clin Epidemiol. 2011 Apr;64(4):401-6
pubmed: 21208779
Gut. 2019 Jul;68(7):1287-1296
pubmed: 30901310
N Engl J Med. 1976 Feb 26;294(9):470-2
pubmed: 173996
Mod Pathol. 2008 Apr;21(4):491-7
pubmed: 18246041
Liver Int. 2019 May;39(5):905-913
pubmed: 30773766
Korean J Intern Med. 2009 Jun;24(2):147-52
pubmed: 19543495
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Gastroenterology. 2009 Nov;137(5):1698-705
pubmed: 19664629
NCHS Data Brief. 2018 Jul;(314):1-8
pubmed: 30044212
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Fam Med. 2005 May;37(5):360-3
pubmed: 15883903
PLoS One. 2018 Jul 27;13(7):e0200776
pubmed: 30052636
J Hepatol. 2016 Aug;65(2):386-98
pubmed: 27085809
HPB (Oxford). 2010 Oct;12(8):509-22
pubmed: 20887318
Liver Int. 2019 Jan;39(1):158-167
pubmed: 30218633
Gastroenterology. 2017 Mar;152(4):880-894.e6
pubmed: 27939373
Br J Surg. 2017 Nov;104(12):1695-1703
pubmed: 28857134
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Ann Surg Oncol. 2009 Mar;16(3):640-8
pubmed: 19130136
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
JAMA. 1979 Aug 17;242(7):644-8
pubmed: 221698
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet. 1973 Oct 27;2(7835):926-9
pubmed: 4126557
Ann Surg Oncol. 2020 Sep;27(9):3330-3338
pubmed: 32542565